Salarius Pharmaceuticals Inc. has announced a Third Amendment to its Agreement and Plan of Merger with Decoy Therapeutics Inc., which allows certain holders of Decoy's non-convertible promissory notes to exchange their debt for shares of Salarius' newly created Series B Non-Voting Convertible Preferred Stock. This amendment, entered on July 18, 2025, maintains the relative ownership percentages of the combined company, with Salarius legacy stockholders retaining 7.6% and Decoy's legacy stockholders holding 92.4% pre-Qualified Financing. The amendment ensures that the number of shares underlying the Series A Preferred Stock, issued to Decoy stockholders and convertible noteholders, will be adjusted to account for the Series B Preferred Stock, preserving the previously disclosed ownership ratios. The company is set to finalize the note exchange agreements immediately after the merger's completion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.